Neurocrine gains BIAL’s Parkinson’s asset Opicapone for North America
By Vipul Sikka
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 5 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2234 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
To add to its neurological disorders portfolio, Neurocrine has entered into a licensing agreement with BIAL for the development and commercialisation of the latter’s Parkinson’s disease asset, opicapone (Ongentys®)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS